特里弗卢诺胺/莱弗卢诺胺通过减少SCLC中DRP1的线粒体碎片化,与化疗药物产生协同作用
Tamara Mirzapoiazova1, Liz Tseng2, Bolot Mambetsariev1
1Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA 91010, USA.
新的SCLC疗法显示出有希望的结果. 勒弗卢诺胺和特里弗卢诺胺通过影响线粒体分裂来抑制癌细胞生长. 在临床前模型中,与卡博普拉丁和卢比内克丁等化疗药物的组合显示出显著的抗瘤作用.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 小细胞肺癌 (SCLC) 经常复发,尽管最初的化疗反应.
- 对SCLC开发新的治疗策略至关重要.
研究的目的:
- 调查莱夫卢诺胺 (Leflu) 和特里弗卢诺胺 (Teri) 对SCLC的抗增殖作用.
- 为了评估Leflu/Teri与化疗剂 (碳白金[Carbo],卢比内克丁[Lur]) 的协同效应.
主要方法:
- 评估了对SCLC细胞增殖的细胞静止作用.
- 测量了DRP1酸化和线粒体碎片化.
- 分析了皮里米丁 de novo路径中间体.
- 在体内评估的抗瘤效应和球状生长.
- 确定了亡和DNA损伤诱导.
主要成果:
- 莱夫卢和特里通过降低DRP1酸化和线粒体碎片化来抑制SCLC细胞增殖.
- Teri plus Carbo协同降低了增殖,DRP1酸化和金胺中间体,同时增加了细胞亡和DNA损伤.
- 莱弗鲁加卡博在体内显示出抗瘤作用.
- 在小鼠瘤中,Lur加Teri协同抑制了球状体生长,并减少了尿素和DRP1酸化.
结论:
- 莱夫卢和特里对SCLC细胞表现出细胞静止作用.
- 将Carbo和Lur与Teri或Leflu结合使用,显示出显著的疗效.
- 准DRP1/DHODH通路和线粒体可塑性为SCLC提供了一个潜在的治疗策略.
更多相关视频
14:51Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
相关概念视频
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Drugs that Stabilize Microtubules
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
